Precision Medicine to Treat Advanced Gastroesophageal Adenocarcinoma: A Work in Progress.

Fecha de publicación: 22/09/2020 Fecha Ahead of Print: 22/09/2020

Autores de INCLIVA

Valentina Gambardella

Autor
Tania Carolina Fleitas Kanonnikoff

Autor
Noelia Tarazona Llavero

Autor
Federica Papaccio

Autor
María Del Sol Huerta Álvaro

Autor
Susana Roselló Keränen

Autor
Francisco Gimeno Valiente

Autor
Desamparados Roda Perez

Autor
Andrés Cervantes Ruiperez

Autor

Grupos y Plataformas de I+D+i

Grupo de Investigación en Cáncer Colorrectal y Nuevos Desarrollos Terapéuticos en Tumores Sólidos

Leading Researcher

Andrés Cervantes Ruiperez
Unidad de Medicina de Precisión

Abstract

Gastroesophageal adenocarcinoma (GEA) represents a heterogeneous disease and, when diagnosed as locally advanced or metastatic, it is characterized by poor prognosis. During the last few years, several molecular classifications have been proposed to try to personalize treatment for those patients diagnosed with advanced disease. Nevertheless, despite the great effort, precision medicine is still far from being a reality. The improvement in the molecular analysis due to the application of high throughput technologies based on DNA and RNA sequencing has opened a novel scenario leading to the personalization of treatment. The possibility to target epidermal growth factor receptor (HER)2, Claudine, Fibroblast Growth Factor Receptors (FGFR), and other alterations with a molecular matched therapy could significantly improve clinical outcomes over advanced gastric cancer patients. On the other hand, the development of immunotherapy could also represent a promising strategy in a selected population. In this review, we sought to describe the novel pathways implicated in GEA progression and the results of the molecular matched therapies.

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/)

Datos de la publicación

ISSN/ISSNe:: 2077-0383, 2077-0383
Tipo:: Article
Páginas:: -
DOI:: 10.3390/jcm9093049
PubMed:: 32971757

Documentos

Published Version

Métricas

Filiaciones

Gambardella, Valentina:: Instituto de Investigación. Department of Medical Oncology, Biomedical Research Institute INCLIVA, University of Valencia, Blasco Ibañez 17, 46010 Valencia, Spain
Fleitas, Tania:: Instituto de Investigación. Department of Medical Oncology, Biomedical Research Institute INCLIVA, University of Valencia, Blasco Ibañez 17, 46010 Valencia, Spain
Tarazona, Noelia:: Instituto de Investigación. Department of Medical Oncology, Biomedical Research Institute INCLIVA, University of Valencia, Blasco Ibañez 17, 46010 Valencia, Spain
Papaccio, Federica:: Instituto de Investigación. Department of Medical Oncology, Biomedical Research Institute INCLIVA, University of Valencia, Blasco Ibañez 17, 46010 Valencia, Spain
Huerta, Marisol:: Instituto de Investigación. Department of Medical Oncology, Biomedical Research Institute INCLIVA, University of Valencia, Blasco Ibañez 17, 46010 Valencia, Spain
Rosello, Susana:: Instituto de Investigación. Department of Medical Oncology, Biomedical Research Institute INCLIVA, University of Valencia, Blasco Ibañez 17, 46010 Valencia, Spain
Gimeno-Valiente, Francisco:: Instituto de Investigación. Department of Medical Oncology, Biomedical Research Institute INCLIVA, University of Valencia, Blasco Ibañez 17, 46010 Valencia, Spain
Roda, Desamparados:: Instituto de Investigación. Department of Medical Oncology, Biomedical Research Institute INCLIVA, University of Valencia, Blasco Ibañez 17, 46010 Valencia, Spain
Cervantes, Andres:: Instituto de Investigación. Department of Medical Oncology, Biomedical Research Institute INCLIVA, University of Valencia, Blasco Ibañez 17, 46010 Valencia, Spain